Ian B. Li

Ian Li joined 1315 Capital in 2015 and is a Principal on the investment team. Prior to investing, Ian was a healthcare management and strategy consultant at Capgemini Consulting and had experience working at Stryker Orthopaedics in the quality engineering department.

Ian currently serves on the board of 3B Scientific, CortiCare, and miraDry, and is a board observer for Seraphina Therapeutics. He previously served on the board of Colorescience (acquired by RoundTable), and was a board observer for Bonafide Health (acquired by Pharmavite), Nutrisense (acquired by Dexcom), and Nutrition 21 (acquired by Everwell Health). Ian also serves on the board of Philadelphia’s Magic Gardens, and is on the leadership team of Out Investors.

Ian received a BSE in Biomedical Engineering from Duke University, with a minor in Economics.